Informed Consent in Clinical Trials: What You’re Agreeing To

Informed consent is the cornerstone of ethical clinical research. The process is designed to ensure that participants understand what they’re agreeing to before enrolling — the trial’s purpose, procedures, risks, benefits, alternatives, and their rights as participants. The consent form is typically a long, detailed document, and the conversation with the study coordinator is meant to clarify the document and answer questions. Understanding informed consent clinical trials requires more than just signing the form — it means reading carefully, asking questions, and recognizing what the document does and doesn’t promise. This guide covers the consent process, what to look for in the form, and your rights as a participant. It is educational information, not legal or medical advice; direct specific questions to the study team and your own clinician. This article is part of our guide to medical conditions.

What informed consent is meant to ensure

The principle of informed consent in research grew out of historical abuses — most notoriously the Tuskegee syphilis study, the Nazi medical experiments, and various other instances where research was conducted on people without their knowledge or true voluntary participation. The Nuremberg Code (1947), the Declaration of Helsinki (1964), and the Belmont Report (1979) established the modern framework requiring voluntary, informed consent for research participation. The Belmont Report distilled this into three principles that still govern research ethics: respect for persons, beneficence, and justice.

The framework requires that participants:

• Understand the research purpose and what’s being tested
• Understand the procedures, risks, and potential benefits
• Understand the alternatives to participating (including standard care without the trial)
• Understand their right to withdraw at any time without penalty
• Have the capacity to make a voluntary decision without coercion
• Have time to consider before deciding

The Common Rule (45 CFR 46) codifies these requirements in US federal regulations, and the FDA’s own regulations (21 CFR 50) apply to studies of drugs, biologics, and devices. Consent must be sought under conditions that give the person enough time to consider whether to take part and that minimize any possibility of coercion or undue influence.

Key information first: the concise summary

A major change took effect when the Common Rule was revised (the “2018 Requirements”). Consent forms must now begin with a concise and focused presentation of the key information a reasonable person would need to decide whether to participate — before the long, detailed sections. In practice this means the opening of the form should quickly convey that the study is research, its purpose and expected duration, the main procedures, the reasonably foreseeable risks, any expected benefits, and the alternatives. The information must be organized and presented in a way that helps you make a decision, not simply drown you in text. If the first page of a consent form doesn’t clearly answer “what is this, what will happen to me, and what could go wrong,” ask the coordinator to walk you through it.

What’s in a typical consent form

Trial consent forms are typically 15-30 pages and contain standardized sections:

Purpose of the research: What the trial is testing and why. Should explain the research question in plain language.

Procedures: What participants will do, including all visits, tests, treatments, and the duration of participation. Should be detailed enough to understand the time commitment.

Risks and discomforts: Known and theoretical risks of the experimental treatment, study procedures, and any risks specific to your situation. Should distinguish between common, less common, and rare risks.

Benefits: Potential direct benefits to you (which may be limited or none in some trials) and benefits to society from the research.

Alternatives: Treatment options outside the trial. The form should make clear what standard care looks like without trial participation.

Confidentiality: How your personal and medical information will be protected, who will have access, and limits on confidentiality.

Costs and compensation: What’s covered by the trial sponsor, what’s billed to insurance, and what compensation you’ll receive. For studies with more than minimal risk, the form must also explain whether any compensation or medical treatment is available if you are injured, and where to get more information.

Voluntary participation: Statement that participation is voluntary and you can withdraw at any time without affecting your medical care.

Contacts: Who to contact with questions about the research and who to contact about your rights as a participant.

Consent form at a glance

Section	The question it should answer
Purpose	What is being studied, and why?
Procedures	What exactly will I do, and for how long?
Risks	What could go wrong, and how likely is it?
Benefits	Could this help me, and could it help others?
Alternatives	What are my options if I don’t join?
Confidentiality	Who sees my data, and how is it protected?
Costs & injury	What will I pay, and what happens if I’m harmed?
Contacts	Who do I call with questions or concerns?

What to read carefully

Some sections deserve particular attention:

Risks section: The full list of potential side effects and adverse events. This is often the longest section and should be read in detail. Note both common risks (which most participants might experience) and serious risks (rare but potentially significant).

Procedures section: The full schedule of visits and what happens at each. Time commitment is often underestimated when only reading the summary. Add up the total visits, hours, and travel.

Withdrawal section: Your right to leave the trial. Confirm there’s no penalty and that withdrawal won’t affect your standard medical care. Note any specific procedures (final visit, return of unused study drug) required for proper withdrawal.

What happens to my data: How long data is retained, whether identifiable data leaves the study site, and whether data may be used for future research beyond the current trial. The revised Common Rule requires the form to state whether identifiers might be removed and the data used for future studies.

Conflicts of interest: Disclosure of financial relationships between the principal investigator and the trial sponsor. Most trials have legitimate financial relationships, but the disclosure helps you evaluate any potential bias.

What questions to ask

Beyond reading the form, ask the study coordinator specific questions:

• “What’s the most common adverse event in this trial so far?”
• “What happens if I experience a serious side effect?”
• “Who pays for medical care for trial-related injuries?”
• “Can I continue my regular medications?”
• “What if my condition worsens during the trial — can I receive standard treatment?”
• “How is randomization done? What’s my probability of receiving the active treatment?”
• “Will I learn whether I received placebo or active treatment after the trial ends?”
• “What happens to me at the trial’s end? Can I continue receiving the experimental treatment if it works?”

Coordinators are accustomed to these questions and should answer them directly. Vague or evasive answers are a red flag.

Teach-back: confirming you actually understand

Consent is meaningless if you don’t understand what you signed. Good study teams use “teach-back” — asking you to explain the study back in your own words — to confirm comprehension rather than just assuming you read the form. You can invite this yourself: after the coordinator explains a section, try summarizing it and ask them to correct anything you got wrong. If a concept (randomization, placebo, “double-blind,” washout period) is unclear, that is exactly what the consent conversation is for. Consent forms are supposed to be written at a general-reader reading level, and study sites must provide help for people who read the language poorly or not at all, including qualified interpreters and translated forms.

The continuous nature of consent

Informed consent isn’t a one-time event at enrollment. The process continues throughout the trial:

• If significant new safety information emerges during the trial, participants must be re-consented with updated information
• Substantial protocol changes require re-consent
• Long-term follow-up may involve separate consent processes
• Participants can ask questions and reconsider participation at any time

If you have new questions or concerns during the trial, raise them. The study team should address them. If you decide to withdraw, you can — at any time, for any reason.

The role of the IRB

An Institutional Review Board (IRB) — sometimes called an ethics committee — reviews and approves every human-subjects study before it can enroll, and continues to monitor it while it runs. The IRB is independent of the sponsor and the investigator, and its job is to protect participants: it evaluates whether risks are minimized and reasonable relative to benefits, whether selection of participants is fair, and whether the consent process and form are adequate. The IRB’s contact information must appear on the consent form so you can reach it directly with concerns about your rights — separate from the research team. If you ever feel pressured, misled, or unsafe, the IRB is the body to contact.

Your rights as a participant

Trial participants have specific rights:

• Right to withdraw at any time without affecting your medical care
• Right to know about new safety information that emerges during the trial
• Right to ask questions and receive answers
• Right to confidentiality of your medical information within the limits of the consent
• Right to know who’s funding the research and any financial conflicts
• Right to receive a copy of the consent form for your records
• Right to ongoing medical care for any trial-related adverse events

If you feel your rights are being violated, contact the IRB. The IRB contact information must be included on the consent form. The IRB exists specifically to protect participant rights independent of the trial sponsor or investigator.

Common consent form red flags

Watch for:

• Pressure to enroll quickly without time to consider
• Discouragement from discussing the trial with your physician
• Vague or evasive answers to specific questions
• Compensation that seems disproportionate to the time commitment
• Missing IRB approval information
• Missing FDA registration (most US trials should be listed on ClinicalTrials.gov)
• Promises of guaranteed benefit (no trial can promise the experimental treatment will help you)

Legitimate trials don’t pressure participants. The study coordinator should support you taking time to read the consent, discuss with family and physicians, and ask questions before deciding.

Verify the trial on ClinicalTrials.gov

Most US clinical trials of drugs, biologics, and devices are required to register on ClinicalTrials.gov, and many are required to post summary results there as well. Before you enroll, you can look the study up by its title or its NCT number (found on the consent form). The listing shows the sponsor, eligibility criteria, study locations, recruitment status, and — for completed studies — outcomes. It’s a useful independent cross-check against what you’re being told in person. If a trial that should be registered can’t be found there, ask why.

Signing the consent — what it does and doesn’t mean

Signing the consent form means:

• You acknowledge reading the form and having questions answered
• You agree to participate under the protocol described
• You authorize use of your medical information as described

Signing the consent form doesn’t mean:

• You waive your right to withdraw
• You waive legal rights regarding negligence or malpractice
• You agree to treatment beyond what’s in the protocol
• You waive your medical care outside the trial

Federal rules are explicit that consent may not include language through which the participant waives, or appears to waive, any legal rights, or releases the investigator, sponsor, or institution from liability for negligence. The consent is a record of your informed agreement, not a contract that binds you against your interests.

Frequently Asked Questions

Can I take the consent form home to read?

Yes. Most trials encourage participants to take time, often days, to review consent before signing. Quick decisions aren’t required and shouldn’t be pressured.

Do I have to discuss with my physician?

Not required, but recommended. Your treating physician can put the trial in context and help you evaluate whether participation makes sense for your situation.

What if I don’t understand the consent form?

Ask the coordinator to explain. Trial coordinators are required to ensure you understand before signing. If language is a barrier, trials typically provide translation and qualified interpreters at no cost to you.

Can someone else consent for me?

Generally no for adult participants who have decision-making capacity. For children, parents or guardians provide permission (and older children give assent). For adults without decision-making capacity (severe dementia, etc.), legally authorized representatives may consent under applicable law.

What if I want to withdraw later?

You can. Notify the study team. Some trials request a final visit for safety follow-up. There’s no penalty for withdrawal, and it will not affect the care you receive outside the study.

Is signing a consent form the same as agreeing to treatment?

No. Research consent covers participation in a study under a specific protocol. It is distinct from the general treatment consent you sign for routine clinical care, and it does not commit you to anything beyond what the protocol describes.

The bottom line on informed consent

Informed consent is the foundation of ethical trial participation. The consent form provides comprehensive information about the trial — risks, benefits, procedures, alternatives, your rights — but reading it carefully and asking questions is essential. You retain rights throughout the trial, including the right to withdraw at any time. Don’t sign quickly under pressure. Take time, discuss with physicians and family, and ensure you understand what you’re agreeing to. The consent process is meant to protect you; use it.

Sources

• U.S. Food & Drug Administration — Informed Consent (guidance for IRBs, clinical investigators, and sponsors) and 21 CFR 50 (verify current version)
• HHS Office for Human Research Protections (OHRP) — Common Rule, 45 CFR 46 and Informed Consent FAQs
• National Institutes of Health / National Cancer Institute — Informed Consent
• ClinicalTrials.gov — study registration and results database
• The Belmont Report (1979) — ethical principles for research involving human subjects